20 results about "Cocrystal" patented technology

This invention discloses a nicotinamide-salicylic acid cocrystal, its preparation method, and its uses, relating to the field of cocrystal technology. The nicotinamide-salicylic acid cocrystal comprises nicotinamide and salicylic acid molecules, and the molecular formula of the nicotinamide-salicylic acid is C0. 13 H 12 N2O4, wherein the molar ratio of nicotinamide to salicylic acid is 1:1; the eutectic is monoclinic, space group P21 / n, with cell parameters a=11.080(2)Å, b=5.0000(10)Å, c=22.820(5)Å, α=90°, β=97.60(3)°, γ=90°, V=1253.1(4)Å. 3 The differential scanning calorimetry (DSC) spectrum of the eutectic showed a characteristic endothermic peak around 142.4 ± 2 °C. This invention addresses the problems of poor stability of nicotinamide, low solubility of salicylic acid, and strong irritation in existing technologies by optimizing intermolecular interactions to form a specific crystal form, thus providing a novel raw material with superior performance for the cosmetics industry. This is achieved through the preparation of a structurally stable, simple, and chemically superior nicotinamide-salicylic acid eutectic with excellent physicochemical properties.

This invention provides urolithin A cocrystals, their preparation methods, compositions, and applications. Specifically, this invention provides a urolithin A cocrystal with high bioavailability, wherein the urolithin A cocrystal is selected from the group consisting of: urolithin A-proline cocrystals, urolithin A-carnitine cocrystals, urolithin A-nicotinamide cocrystals, or urolithin A-creatine cocrystals. Compared to urolithin itself, the urolithin A cocrystals of this invention exhibit high stability, a significantly lower melting point, and significantly improved solubility and bioavailability. Furthermore, the preparation method is simple, easy to control, and has good reproducibility, allowing for stable acquisition of the target cocrystal. The composition containing the cocrystal, prepared by grinding, has high yield, low cost, and is suitable for large-scale production.

A cocrystal of a compound useful for treating cancer and a process for its preparation, pharmaceutical compositions thereof, and use for cancer treatment comprising administering the cocrystal described herein to a patient in need are provided.

The invention relates to solid forms of a compound useful for the treatment of cancer, pharmaceutical compositions thereof, and methods of cancer treatment comprising the administration of said solid forms to a patient in need.

Disclosed herein are various solid forms of Compound A, including crystalline and amorphous forms of Compound A free base, as well as salt forms, cocrystals, and solvates thereof. Also disclosed are methods of making the salt, cocrystal, and solvate forms, and methods of treating diseases and disorders with the salt, cocrystal, and solvate forms (Compound A).

This invention discloses a starch-plant polyphenol cocrystal, its preparation method, and its application in functional foods, relating to the field of functional food technology. The preparation method includes: S1, mixing starch and plant polyphenols uniformly to obtain a mixture; S2, adding the mixture to a low-temperature impact mill, adding grinding media, and introducing an inert gas into the low-temperature impact mill to subject the mixture to impact treatment, obtaining a cocrystal complex; S3, purifying and freeze-drying the cocrystal complex to obtain the starch-plant polyphenol cocrystal. This invention innovatively uses wheat starch and proanthocyanidins to form a cocrystal structure, resulting in a simpler and more efficient preparation process, eliminating the need for complex physical field treatments or multiple freeze-drying steps, and maximizing the preservation of polyphenol activity. The cocrystal structure endows the carrier with excellent sustained-release performance, enabling long-term release of polyphenols in functional food applications, solving the problems of unstable loading rates and poor sustained-release effects in existing technologies.

The present invention relates to a cocrystal of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevixibat) and pyridoxine. The invention also relates to a pharmaceutical composition comprising said cocrystal, and to its use in the treatment of various conditions as described herein.

A cocrystal, comprising a compound of formula 1 and oxalic acid.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and / or hydrate, and / or cocrystal, and / or drug combination of the compound) that inhibit RNA polymerase I (Pol I). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) Pol I activity contributes to the pathology and / or symptoms and / or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

The application belongs to the technical field of pharmaceutical chemistry and crystallization process, and particularly relates to a vitamin D3 cholesterol co-crystal as well as a preparation method and application thereof. By constructing a stable co-crystal structure with a molar ratio of vitamin D3 to cholesterol being 1:1, trace colored impurities and process impurities in raw materials are removed by activated carbon adsorption, and further, residual microparticles and heterogeneous nucleation sites are removed above the crystallization point by heat preservation filtration, so that the high purity and uniformity of the co-crystal precursor solution are ensured from the source. On this basis, the rigid steroidal skeleton of cholesterol builds an effective crystallographic barrier for the fragile active part of vitamin D3 through close intermolecular packing and van der Waals force interaction, so as to reduce the risk of oxidation and isomerization degradation of vitamin D3 from the physical and chemical double aspects, improve the chemical stability, and thus ensure the high chemical purity and biological activity, so as to provide an active ingredient with more reliable quality and more stable curative effect for the treatment of calcium deficiency related diseases, and has a good medicinal application prospect.

The present invention provides a volume-weighted average diameter D 4,3 and comprising at least 50% by weight of malate particles, the malate particles comprising at least 70% by weight of a co-crystal of malic acid and an alkali metal hydrogen malate, the particulate composition being advantageously deposited in or on a confectionery product.

The present application provides a nitrogen heterocyclic compound or a pharmaceutically acceptable salt, solvate, hydrate, polymorphic substance, cocrystal, tautomer, stereoisomer or isotope compound thereof. The nitrogen heterocyclic compound has a structure represented by formula I. The nitrogen heterocyclic compound provided by the present application can be used for removing aging cells.

The present disclosure is directed to ʟ‑Ergothioneine hemiascorbic acid, a cocrystal monohydrate form, and processes for the preparation of the cocrystal monohydrate form.

This invention discloses a nicotine-ascorbic acid eutectic, whose X-ray diffraction pattern has characteristic peaks at one or more locations with diffraction angles 2θ of 11.572±0.2°, 14.512±0.2°, 16.415±0.2°, 18.523±0.2°, 31.263±0.2°, 33.223±0.2°, 37.654±0.2°, 41.027±0.2°, and 45.152±0.2°. This invention also discloses a method for preparing the nicotine-ascorbic acid cocrystal, comprising the following steps: a. mixing nicotine and ascorbic acid at a molar ratio of 2:1 to 1:2; b. adding solvent and then dissolving the mixture completely using magnetic stirring or ultrasound; c. allowing the mixture to cool and stand under light-protected conditions to allow the solvent to evaporate and crystals to precipitate; d. separating, washing, and drying the crystals to obtain the nicotine-ascorbic acid cocrystal. This invention also discloses tobacco products containing the nicotine-ascorbic acid cocrystal. The nicotine-ascorbic acid cocrystal disclosed in this invention exhibits good storage stability and, when used in tobacco products, can achieve both initial rapid release and sustained stable release, achieving a balance between release and absorption, and demonstrating high bioavailability.

This invention belongs to the field of pharmaceutical chemistry and crystallization technology, specifically disclosing a clonidine-fumaric acid cocrystal, its preparation method, and its application. The molar ratio of clonidine to fumaric acid is 1:2. This invention achieves precise control of clonidine's solubility and long-lasting sustained release by combining clonidine and fumaric acid in a 1:2 molar ratio to form a cocrystal, without altering the pharmacological activity of clonidine. Furthermore, the preparation method is simple and suitable for industrial production.

A medicament for treatment or prevention of porphyria, comprising 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid or a pharmaceutically acceptable salt or cocrystal thereof as an active ingredient, wherein the dose of the 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid or the pharmaceutically acceptable salt or cocrystal thereof is 50 to 500 mg / day.

This invention belongs to the field of pharmaceutical cocrystal technology, specifically relating to an apixaban-gallic acid cocrystal solvate and its preparation method. The cocrystal solvate is formed by apixaban and gallic acid in a 1:1 molar ratio, simultaneously binding one molecule of acetone and one molecule of water. Its X-ray powder diffraction pattern exhibits characteristic peaks at 2θ values ​​of 8.3±0.2°, 11.3±0.2°, 12.7±0.2°, 13.8±0.2°, 16.8±0.2°, 18.3±0.2°, 22.0±0.2°, and 26.9±0.2°. The crystal form provided by this invention significantly improves the solubility of apixaban, resulting in tablets prepared with it as the active ingredient exhibiting high dissolution rate and high bioavailability, making it more suitable for oral formulations.